Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Mental health problems spell trouble for diabetics

22 Nov 2020
5 ways to diminish the anxiety of your perioperative patient

Mental health comorbidities are common among patients with type 2 diabetes mellitus (T2DM) and may lead to worse outcomes, a recent study has found.

This suggests that the management of T2DM should also include screening for mental health problems, so that interventions may be delivered in a timely manner.

The researchers conducted a retrospective observational analysis of 63,365 T2DM patients (mean age, 69.9±12.1 years; 54.0 percent male). Most (n=51,335) were without mental health comorbidities, which included depression, anxiety, schizophrenia, or substance use disorder.

In the remaining 12,030 patients, depression (13.6 percent) and anxiety (3.17 percent) were the most common comorbidities. The presence of such comorbidities increased the risk of all T2DM outcomes assessed in the study.

For example, the risk of 4-year all-cause mortality was significantly elevated in T2DM patients with at least one mental health comorbidity (adjusted odds ratio [OR], 1.24, 95 percent confidence interval [CI], 1.16–1.31; p<0.001), though different comorbidities led to different magnitudes of effect. Substance use disorder most strongly affected mortality risk.

Moreover, having at least one mental health comorbidity likewise increased the risk of all-cause hospitalization (adjusted OR, 1.16, 95 percent CI, 1.10–1.23; p<0.001), T2D hospitalization (adjusted OR, 1.51, 95 percent CI, 1.18–1.93; p=0.001), and emergency room visits (adjusted OR, 1.26, 95 percent CI, 1.21–1.32; p<0.001) among T2D patients. For all above outcomes, substance use disorder was the strongest risk factor.

“These findings underline the need for developing global management strategies to facilitate the prevention, early detection, diagnosis and monitoring of mental health comorbidities in T2D patients,” the researchers said.

“The high prevalence of multimorbidity found in T2D patients highlights the importance of providing continuity of care and person-centred approaches to improve the management and outcome of this chronic disease,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.